Complex Medicinal Products - the Other 'Biosimilar'
By Douglas W. Balogh, PhD -
Published 21 December 2016
This article discusses Non-Biological Complex Drugs (NBCDs) and how FDA and other regulatory agencies review and approve generic forms of these products.
Categories: Features, US, FDA, Generic drugs, Regulatory strategy, Submission and registration
Tags: Non-Biological Complex Drugs, NBCD